Detaillierte Beitrags-Information

Zurück zur Liste

Beitragstitel A case report of bacteriophage therapy in multi-resistant pseudomonas aeruginosa external ear infection with a systematic review of the literature
Beitragscode P09
Autor:innen
  1. Sara-Lynn Hool Inselspital, Bern University Hospital Präsentierende:r
  2. Prosper Konu HFR Fribourg - Hôpital cantonal
  3. Veronique Erard HFR Fribourg - Hôpital cantonal
  4. Marco Caversaccio Inselgruppe AG, Inselspital Universitäts HNO-Klinik Bern
  5. Florian Lang Centre Interdisciplinaire d'ORL CIORL
Präsentationsform Poster
Themengebiete
  • SGORL - Schwindel und Gleichgewicht
Abstract-Text Introduction
The treatment of chronic otitis externa infected with multi-resistant pseudomonas aeruginosa (PA) can be challenging. Since the 1930s bacteriophage treatment has been proposed. We report one case with a systematic review of the literature on bacteriophage treatment in chronic otitis externa.

Methods
Our patient, a 74 years old male, with hearing aids, 12 years after radiotherapy presents a chronic otitis externa with osteitis due to a multi-resistant PA on the right ear resistant to conventional therapy since 3 years.
A systematic review was performed using a search in pubmed with the keywords “bacteriophage” and “otitis” or “ear”. We included references from identified articles that were cross referenced.

Results
Our patient received off label a phage cocktail applied topically. After 1 month of treatment no multi-resistant PA can be detected anymore and the ear remains dry after a follow up of 3 months. No side effects were detected. A total of 70 articles were identified. Only 2 articles fitted the required criteria with 13 human cases treated with bacteriophage for an external ear infection. Treated patients showed significant improvement after treatment. 4 cases showed complete remission of the infection.

Conclusion
Bacteriophage therapy is a possible alternative tool for the treatment of therapy-resistant otitis externa with multi-resistant PA. Further prospective randomized trials are required to evaluate in which cases this therapy should be used and to standardize the therapy modalities.